Literature DB >> 31372262

Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients.

Tao Chen1, Fangyu Zhou1, Weili Jiang2,3, Rui Mao1, Hui Zheng1, Linlin Qin1, Chang Chen1.   

Abstract

BACKGROUND: The incidence of lung cancer is reported as age dependent. However, the link between survival and age at diagnosis remains controversial. To date, few studies have examined the relationship between age and the clinicopathologic characteristics of patients with non-small cell lung cancer (NSCLC).
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we included in our analysis 151,919 patients diagnosed with NSCLC between 2004 and 2013. Logistic regression was used to evaluate the associations between age and clinicopathological characteristics. N and M stages were separately assessed in each T stage.
RESULTS: Of the patients enrolled, 60,271 patients were diagnosed at the M1 stage, 147,263 patients had lymph node metastasis, and 49,862 patients underwent surgery. Younger age was inversely associated with high N stage and M stage (P<0.001, respectively). For each T stage, the inverse associations with M1 stage and lymph node metastasis were also presented (P<0.001, respectively). Age was an independent risk predictor for NSCLC patients by using univariate and multivariate analyses.
CONCLUSIONS: Age at diagnosis is a heterogeneous factor for NSCLC patients: younger patients have an increased risk of lymph node and distant metastases, yet have a better prognosis.

Entities:  

Keywords:  Age at diagnosis; distant metastasis; lymph node metastasis; non-small cell lung cancer (NSCLC); prognosis

Year:  2019        PMID: 31372262      PMCID: PMC6626822          DOI: 10.21037/jtd.2019.06.24

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  33 in total

1.  Combinations of glutathione S-transferase genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study.

Authors:  M L Cote; S L R Kardia; A S Wenzlaff; S J Land; A G Schwartz
Journal:  Carcinogenesis       Date:  2005-01-20       Impact factor: 4.944

2.  Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.

Authors:  L Kristin Newby; Nancy M Allen LaPointe; Anita Y Chen; Judith M Kramer; Bradley G Hammill; Elizabeth R DeLong; Lawrence H Muhlbaier; Robert M Califf
Journal:  Circulation       Date:  2006-01-09       Impact factor: 29.690

3.  Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.

Authors:  Scott D Ramsey; Nadia Howlader; Ruth D Etzioni; Bonnie Donato
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

4.  Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.

Authors:  Christer Sederholm; Gunnar Hillerdal; Kristina Lamberg; Karl Kölbeck; Monika Dufmats; Ronny Westberg; Sulochana R Gawande
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

5.  The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.

Authors:  M G Statius Muller; P A van Leeuwen; E S de Lange-De Klerk; P J van Diest; R Pijpers; C C Ferwerda; R J Vuylsteke; S Meijer
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

6.  Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Authors:  Z M Chen; L X Jiang; Y P Chen; J X Xie; H C Pan; R Peto; R Collins; L S Liu
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

7.  Non-small cell lung cancer in very young and very old patients.

Authors:  C W Kuo; Y M Chen; J Y Chao; C M Tsai; R P Perng
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

8.  Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma.

Authors:  Kuan-Yu Chen; Chia-Hsuin Chang; Chong-Jen Yu; Sow-Hsong Kuo; Pan-Chyr Yang
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

9.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

Authors:  K S Albain; J J Crowley; M LeBlanc; R B Livingston
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

10.  Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.

Authors:  Taofeek K Owonikoko; Camille C Ragin; Chandra P Belani; Ana B Oton; William E Gooding; Emanuela Taioli; Suresh S Ramalingam
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

View more
  5 in total

Review 1.  Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival.

Authors:  Shadi Hamouri; Nasr Alrabadi; Sebawe Syaj; Hassan Abushukair; Obada Ababneh; Leen Al-Kraimeen; Majd Al-Sous; Erich Hecker
Journal:  Surg Today       Date:  2022-01-09       Impact factor: 2.549

2.  The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy.

Authors:  Tao Zhang; Nan Bi; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Zefen Xiao; Zhouguang Hui; Jima Lv; Xin Wang; Lei Deng; Wenqing Wang; Wenyang Liu; Jianyang Wang; Yirui Zhai; Luhua Wang
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

3.  'Care for Outcomes': systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer.

Authors:  Christine M Cramer-van der Welle; Lotte van Loenhout; Ben Eem van den Borne; Franz Mnh Schramel; Lea M Dijksman
Journal:  BMJ Open       Date:  2021-01-15       Impact factor: 2.692

4.  Factors associated with diagnosis of stages I and II lung cancer: a multivariate analysis.

Authors:  Isabel Cristina Martins Emmerick; Anupama Singh; Maggie Powers; Feiran Lou; Poliana Lin; Mark Maxfield; Karl Uy
Journal:  Rev Saude Publica       Date:  2021-12-17       Impact factor: 2.106

Review 5.  Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer.

Authors:  Joel Rivera-Concepcion; Dipesh Uprety; Alex A Adjei
Journal:  Cancer Res Treat       Date:  2022-02-18       Impact factor: 5.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.